Product Details
| Alternative Name: | Interferon-α-2b |
| |
| MW: | ~21kDa |
| |
| Source: | Produced in HEK cells. The human cytokine (aa 24-188) is fused at the N-terminus to a FLAG®-tag followed by an 8 AA linker. |
| |
| UniProt ID: | P01563 |
| |
| Concentration: | 0.1 mg/ml when reconstituted as suggested. |
| |
| Formulation: | Lyophilized. In PBS. |
| |
| Purity: | ≥90% (SDS-PAGE) |
| |
| Purity Detail: | Affinity purified. |
| |
| Endotoxin Content: | <0.1EU/µg protein (LAL test) |
| |
| Activity: | >5000 IU/µg |
| |
| Reconstitution: | Reconstitute with 100µl sterile distilled water. |
| |
| Shipping: | Blue Ice |
| |
| Short Term Storage: | -20°C |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -80°C. |
| |
| Scientific Background: | IFN-α-2 is a cytokine that displays antiviral and antiproliferative properties. It is comprised of three major subtypes, which include IFN-α-2a, IFN-α-2b, and IFN-α-2c. IFN-α-2b is the predominant subtype in the human genome. It binds to its receptor and activates the JAK-STAT pathway, which stimulates expression of the host genes responsible for antiviral activity. IFN-α-2b is used to treat many diseases, such as hepatitis B and C, melanoma, Kaposi's sarcoma, chronic myeloid lymphoma, and angioblastoma. The combination of IFN-α-2b with ribavirin, a viral inhibitor, has become the standard treatment for chronic hepatitis C virus infection. |
| |
| Technical Info/Product Notes: | FLAG® is a registered trademark of Sigma-Aldrich Co. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Coomassie stained SDS-PAGE. Lane 1, Molecular weight marker. Lane 2, 1.0µg Human IFN-α-2b (ENZ-PRT192).
ENZ-PRT192 activity was determined by comparing against the WHO International Standard for Interferon Alpha 2b (NIBSC, Code 95/566) using the HEK-Blue™ hTLR5 reporter cell line (Invivogen). Briefly, cells were plated at 50,000 cells per well in 100μl of test media. Known amounts of WHO standard and serially diluted ENZ-PRT192 were added in a volume of 100μl. The cells were grown for 20-24 hours at 37°C + 5% CO2. After incubation, 180μl of Quanti-Blue™ was added to 20μl of HEK-Blue™ hTLR5 reporter cell supernatant and the color was allowed to develop for 3 hours at 37°C + 5% CO2. Activity was determined by interpolating the OD at 650nm of the ENZ-PRT192 titer off of the WHO standard curve.
Please mouse over
General Literature References
Heterologous expression, immunochemical and computational analysis of recombinant human interferon alpha 2b: I. Gull, et al.; SpringerPlus
2, 264 (2013),
Abstract;
Full Text
Variants in interferon-α pathway genes and response to pegylated-interferon-α2a plus ribavirin for treatment of chronic HCV infection in the HALT-C trial: T.M. Welzel, et al.; Hepatology
49, 1847 (2009),
Abstract;
Full Text
Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop: R.T. Chung, et al. ; Hepatology
47, 306 (2008),
Full Text
Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells: M. Loignon, et al.; BMC Biotechnology
8, 65 (2008),
Abstract;
Full Text
Identification of nine interferon-α subtypes produced by Sendai virus-induced human peripheral blood leucocytes: T.A. Nyman, et al.; Biochem. J.
329, 295 (1998),
Abstract;
Full Text
Related Products
